Eiko Lifesciences Ltd
Incorporated in 2021, Eiko LifeSciences
Ltd manufacturing & sells Specialty
Chemical and Fine Chemicals[1]
- Market Cap ₹ 65.0 Cr.
- Current Price ₹ 44.4
- High / Low ₹ 64.4 / 43.0
- Stock P/E 16.4
- Book Value ₹ 47.1
- Dividend Yield 0.00 %
- ROCE 7.70 %
- ROE 5.78 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Stock is trading at 0.94 times its book value
- Company is expected to give good quarter
- Company's working capital requirements have reduced from 155 days to 89.8 days
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding is low: 39.9%
- Company has a low return on equity of 3.62% over last 3 years.
- Earnings include an other income of Rs.2.25 Cr.
- Company has high debtors of 164 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Specialty Chemicals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.11 | 0.58 | 0.40 | 0.51 | 0.39 | 0.00 | 11.99 | 25.41 | 18.32 | 27.93 | 32.49 | 42.13 | 48.85 | |
| 0.08 | 0.47 | 0.14 | 0.18 | 0.20 | 0.17 | 11.47 | 24.10 | 17.35 | 26.31 | 30.78 | 38.77 | 45.11 | |
| Operating Profit | 0.03 | 0.11 | 0.26 | 0.33 | 0.19 | -0.17 | 0.52 | 1.31 | 0.97 | 1.62 | 1.71 | 3.36 | 3.74 |
| OPM % | 27.27% | 18.97% | 65.00% | 64.71% | 48.72% | 4.34% | 5.16% | 5.29% | 5.80% | 5.26% | 7.98% | 7.66% | |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.43 | 0.46 | 0.67 | 0.85 | 0.18 | 1.37 | 2.13 | 2.25 | |
| Interest | 0.00 | 0.00 | 0.02 | 0.05 | 0.03 | 0.07 | 0.09 | 0.48 | 0.16 | 0.15 | 0.13 | 0.19 | 0.19 |
| Depreciation | 0.00 | 0.00 | 0.02 | 0.06 | 0.06 | 0.06 | 0.06 | 0.56 | 0.63 | 0.66 | 0.63 | 0.59 | 0.60 |
| Profit before tax | 0.03 | 0.11 | 0.22 | 0.22 | 0.10 | 0.13 | 0.83 | 0.94 | 1.03 | 0.99 | 2.32 | 4.71 | 5.20 |
| Tax % | 33.33% | 27.27% | 27.27% | 13.64% | 30.00% | 0.00% | 26.51% | 24.47% | 25.24% | 23.23% | 24.57% | 23.99% | |
| 0.02 | 0.08 | 0.17 | 0.18 | 0.07 | 0.13 | 0.61 | 0.71 | 0.77 | 0.75 | 1.74 | 3.58 | 3.95 | |
| EPS in Rs | 0.04 | 0.16 | 0.34 | 0.28 | 0.11 | 0.20 | 0.95 | 0.51 | 0.55 | 0.64 | 1.40 | 2.50 | 2.81 |
| Dividend Payout % | 0.00% | 0.00% | 44.41% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 54% |
| 5 Years: | 29% |
| 3 Years: | 32% |
| TTM: | 67% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 46% |
| 5 Years: | 42% |
| 3 Years: | 68% |
| TTM: | 117% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -13% |
| 3 Years: | -10% |
| 1 Year: | -20% |
| Return on Equity | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 3% |
| 3 Years: | 4% |
| Last Year: | 6% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.02 | 3.02 | 3.02 | 3.82 | 3.82 | 3.82 | 3.82 | 8.32 | 8.32 | 12.87 | 13.76 | 14.35 |
| Reserves | 0.02 | 0.10 | 0.21 | 1.73 | 1.61 | 1.66 | 8.71 | 20.31 | 21.11 | 37.81 | 42.66 | 53.16 |
| 0.00 | 0.25 | 0.41 | 0.37 | 0.31 | 0.26 | 1.83 | 4.63 | 0.05 | 0.00 | 1.75 | 1.67 | |
| 0.01 | 0.02 | 0.12 | 0.06 | 0.02 | 0.02 | 2.25 | 1.64 | 1.57 | 2.06 | 2.21 | 13.61 | |
| Total Liabilities | 3.05 | 3.39 | 3.76 | 5.98 | 5.76 | 5.76 | 16.61 | 34.90 | 31.05 | 52.74 | 60.38 | 82.79 |
| 0.00 | 0.00 | 0.49 | 0.43 | 0.37 | 0.31 | 0.25 | 14.29 | 13.88 | 13.57 | 14.26 | 13.67 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.26 | 2.59 | 2.45 | 3.58 | 2.13 | 0.50 | 0.22 | 0.20 | 0.05 | 4.02 | 7.07 | 15.15 |
| 2.79 | 0.80 | 0.82 | 1.97 | 3.26 | 4.95 | 16.14 | 20.41 | 17.12 | 35.15 | 39.05 | 53.97 | |
| Total Assets | 3.05 | 3.39 | 3.76 | 5.98 | 5.76 | 5.76 | 16.61 | 34.90 | 31.05 | 52.74 | 60.38 | 82.79 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.05 | 0.19 | 0.19 | 0.24 | -0.19 | 0.77 | -0.83 | -7.73 | 4.22 | -7.08 | 2.05 | 6.92 | |
| -2.75 | 0.05 | -0.38 | -1.33 | -0.43 | -0.65 | -2.94 | 0.59 | 0.87 | -0.55 | -9.85 | -11.21 | |
| 2.80 | 0.25 | 0.15 | 1.82 | -0.08 | -0.13 | 7.81 | 3.28 | -4.70 | 20.36 | 5.97 | 6.33 | |
| Net Cash Flow | 0.01 | 0.49 | -0.04 | 0.72 | -0.71 | -0.01 | 4.05 | -3.85 | 0.40 | 12.73 | -1.83 | 2.04 |
| Free Cash Flow | -0.05 | 0.19 | -0.33 | 0.24 | -0.19 | 0.77 | -0.83 | -7.88 | 4.00 | -7.43 | 0.72 | 6.92 |
| CFO/OP | -133% | 191% | 96% | 85% | -84% | -459% | -125% | -574% | 427% | -435% | 137% | 235% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 331.82 | 0.00 | 0.00 | 0.00 | 74.87 | 103.81 | 65.50 | 141.66 | 171.59 | 113.92 | 163.66 | |
| Inventory Days | 2.06 | 88.26 | 20.64 | 48.70 | 50.23 | 38.86 | ||||||
| Days Payable | 65.30 | 21.82 | 23.82 | 19.82 | 13.87 | 121.67 | ||||||
| Cash Conversion Cycle | 331.82 | 0.00 | 0.00 | 0.00 | 74.87 | 40.57 | 131.94 | 138.48 | 200.46 | 150.28 | 80.85 | |
| Working Capital Days | 298.64 | 12.59 | 127.75 | 200.39 | 561.54 | 133.34 | 89.20 | 149.23 | 210.14 | 166.04 | 89.84 | |
| ROCE % | 1.84% | 3.43% | 6.85% | 5.65% | 2.23% | 3.48% | 9.15% | 5.88% | 3.70% | 2.84% | 3.84% | 7.70% |
Insights
In beta| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Export Revenue Share % |
|
||||
| Number of Permanent Employees count |
|||||
Extracted by Screener AI
Documents
Announcements
-
Compliance Under Regulation 36 Of The SEBI (Listing Obligations And Disclosures Requirements) Regulations, 2015 ('The Listing Regulations')
- Eiko Lifesciences sent AGM notice; 49th AGM on 22 September 2026, with e-voting from 19-21 September.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Newspaper Advertisement for 49th Annual General Meeting (AGM) of the Company scheduled to be held on Tuesday, 22nd day of September, 2026 at 04:00 P.M. …
- Reg. 34 (1) Annual Report.
- 49Th Annual General Meeting Of The Company Will Be Held On Tuesday, 22Nd Day Of September, 2026 At 04:00 P.M. (IST) Through Video Conferencing/ Other Audio Visual Means.
-
Announcement under Regulation 30 (LODR)-Resignation of Director
- Ms. Hasti Doshi resigned as Independent Director effective 24 August 2026 due to career commitments.
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
Business Overview:[1]
ELL is in the business of manufacturing, processing, formulating, producing, buying, selling, and exporting specialty and Fine Chemicals comprising organic & inorganic chemicals, and Pharma Intermediates, etc.